Puma Biotech Q2 2021 GAAP net loss $5.1M vs prior-year profit; NERLYNX flat at $48.9M

PUMA BIOTECHNOLOGY, INC.

2021-Q2 EPS reported $0.28 revenue$151,553,000

GAAP net loss of $5.1M ($0.13 loss/share) vs net income of $3.4M in Q2 2020.
Non-GAAP adjusted net income $13.1M ($0.32/share) vs $14.0M ($0.36/share) in Q2 2020.
NERLYNX net revenue $48.9M, essentially flat vs $48.8M in Q2 2020.
Cash & securities $108.9M at June 30, 2021, up from $93.4M at Dec 31, 2020.
Received label expansion for NERLYNX dose escalation; SUMMIT top-line data expected Q4 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.